alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014245EN.01000401.xml

| 28.7.2014 | EN | Official Journal of the European Union | C 245/4 |
| --- | --- | --- | --- |

28.7.2014

EN

Official Journal of the European Union

C 245/4

---

Request for a preliminary ruling from the Fővárosi Közigazgatási és Munkaügyi Bíróság (Hungary) lodged on 22 April 2014 — János Kárász v Nyugdíjfolyósító Igazgatóság

(Case C-199/14)

2014/C 245/05

Language of the case: Hungarian

Referring court

Referring court

Fővárosi Közigazgatási és Munkaügyi Bíróság

Parties to the main proceedings

Parties to the main proceedings

Applicant: János Kárász

Applicant:

Defendant: Nyugdíjfolyósító Igazgatóság

Defendant:

Question referred

Question referred

May Article 17 of the Charter of Fundamental Rights of the European Union be interpreted as meaning that cases of cessation, interruption or suspension of the payment of a retirement pension to which an entitlement has arisen because a certain age has been reached constitute an infringement of the right to property laid down in that provision?

---
### IN THE

TENTH COURT OF APPEALS

No. 10

- 21

- 00079

- CV

WILBERT NORWOOD STARKS

, Appellant

v.

DAWSON INDEPENDENT SCHOOL DISTRICT,

NAVARRO COUNTY, AND

NAVARRO COLLEGE

, Appellee s

From the 13th District Court

Navarro County, Texas

Trial Court No. D 48685

- TX

MEMORANDUM OPINION

Wilbert Norwood Starks’s notice of appeal was filed on April 1, 2021

. In a letter

dated April 15, 2021 , the Clerk of this Court notified Starks that the appeal was subject to

dismissal because it appeared the notice of appeal was untimely. The trial court’s

Judgment in this case was signed on October 30, 2020. Starks ’s notice of appea l was due

November 30, 2020. See T EX

. R. A PP

. P . 26.1.

In the same letter, Starks was also warned that the Court would dismiss the appealStarks v. Dawson I .S.D.

, et al. Page 2 without further notification unless, within 14 days from the date of the letter, a response

was filed showing groun ds for continuing the appeal. Starks timely responded but did

not show grounds for continuing the appeal.

Accordingly, this appeal is dismissed for want of jurisdiction.

TOM GRAY

Chief Justice

Before Chief Justice Gray,

Justice Neill , and

Justice Johnson

Appeal dismissed

Opinion delivered and filed May 12 , 2021

[CVO6]
---

EXHIBIT 13.A


CERTIFICATION PURSUANT TO 
    18 U.S.C. SECTION 1350, 
    AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with Annual Report of Petaquilla Minerals Ltd. (the Company) on Form 20-F for the fiscal period ended May 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Joao Manuel, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge: 1.
    The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and2.
    The information contained in the Report fairly presents, in all materials respects, the financial condition and results of operations of the Company.
  /s/Joao Manuel 
    Joao Manuel
    (principal executive officer) 
    Dated: August 30, 2010
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS IN THE QUARTERLY REPORT ON FORM 10-Q OF DIGITAL MICROWAVE
CORPORATION FOR THE QUARTER ENDED JUNE 30, 1998 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-1999
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               JUN-30-1998
<CASH>                                          25,293
<SECURITIES>                                     6,637
<RECEIVABLES>                                   79,409
<ALLOWANCES>                                     6,083
<INVENTORY>                                     88,650
<CURRENT-ASSETS>                               177,445
<PP&E>                                          97,547
<DEPRECIATION>                                  47,984
<TOTAL-ASSETS>                                 274,991
<CURRENT-LIABILITIES>                           62,938
<BONDS>                                            796
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           614
<OTHER-SE>                                     210,643
<TOTAL-LIABILITY-AND-EQUITY>                   274,991
<SALES>                                         63,211
<TOTAL-REVENUES>                                63,211
<CGS>                                           49,502
<TOTAL-COSTS>                                   49,502
<OTHER-EXPENSES>                                30,068
<LOSS-PROVISION>                                 1,838
<INTEREST-EXPENSE>                                  31
<INCOME-PRETAX>                               (15,454)
<INCOME-TAX>                                        28
<INCOME-CONTINUING>                           (15,482)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (15,482)
<EPS-BASIC>                                     (0.25)
<EPS-DILUTED>                                   (0.25)


</TABLE>
§ 211.198 Complaint files. ( a ) Written procedures describing the handling of all written and oral complaints regarding a drug product shall be established and followed. Such procedures shall include provisions for review by the quality control unit, of any complaint involving the possible failure of a drug product to meet any of its specifications and, for such drug products, a determination as to the need for an investigation in accordance with § 211.192. Such procedures shall include provisions for review to determine whether the complaint represents a serious and unexpected adverse drug experience which is required to be reported to the Food and Drug Administration in accordance with §§ 310.305 and 514.80 of this chapter.
( b ) A written record of each complaint shall be maintained in a file designated for drug product complaints. The file regarding such drug product complaints shall be maintained at the establishment where the drug product involved was manufactured, processed, or packed, or such file may be maintained at another facility if the written records in such files are readily available for inspection at that other facility. Written records involving a drug product shall be maintained until at least 1 year after the expiration date of the drug product, or 1 year after the date that the complaint was received, whichever is longer. In the case of certain OTC drug products lacking expiration dating because they meet the criteria for exemption under § 211.137, such written records shall be maintained for 3 years after distribution of the drug product. ( 1 ) The written record shall include the following information, where known: the name and strength of the drug product, lot number, name of complainant, nature of complaint, and reply to complainant.
( 2 ) Where an investigation under § 211.192 is conducted, the written record shall include the findings of the investigation and followup. The record or copy of the record of the investigation shall be maintained at the establishment where the investigation occurred in accordance with § 211.180(c).
( 3 ) Where an investigation under § 211.192 is not conducted, the written record shall include the reason that an investigation was found not to be necessary and the name of the responsible person making such a determination.
[43 FR 45077, Sept. 29, 1978, as amended at 51 FR 24479, July 3, 1986; 68 FR 15364, Mar. 31, 2003]
EXHIBIT 32
----------




                           CERTIFICATIONS OF
          CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                  PURSUANT TO 18 U.S.C. SECTION 1350,
              AS ADOPTED PURSUANT TO SECTION 906 OF THE
                      SARBANES-OXLEY ACT OF 2002
          ---------------------------------------------------



     The following statement is provided by the undersigned to accompany
the Quarterly Report on Form 10-Q for the quarter ended March 31, 2005,
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be
deemed filed pursuant to any provision of the Securities Exchange Act of
1934 or any other securities law:

     Each of the undersigned certifies that the foregoing Report on
Form 10-Q fully complies with the requirements of Section 13(a) of the
Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information
contained in the Form 10-Q fairly presents, in all material respects, the
financial condition and results of operations of ARVIDA/JMB PARTNERS, L.P.




                                       /s/   Gary Nickele
                                       ------------------------------
                                       Gary Nickele
                                       Chief Executive Officer




                                       /s/   Gailen J. Hull
                                       ------------------------------
                                       Gailen J. Hull
                                       Chief Financial Officer and
                                       Principal Accounting Officer
IN THE SUPREME COURT OF PENNSYLVANIA

MIDDLE DISTRICT

JPMORGAN CHASE BANK, NATIONAL 

ASSOCIATION,

Respondent

v.

SEAN GALLAGHER AND HAIRONG 

WANG,

Petitioners

:

:

:

:

:

:

:

:

:

:

:

:

:

No. 319 MAL 2019

Petition for Allowance of Appeal from 

the Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 16th day of October, 2019, the Petition for Allowance of Appeal is 

DENIED.
#### § 501.103 Petitions requesting exemptions from or special requirements for label declaration of ingredients.

The Commissioner of Food and Drugs, either on his own initiative or on behalf of any interested person who has submitted a petition pursuant to part 10 of this chapter may issue a proposal to amend § 501.4 to specify the manner in which an ingredient(s) shall be declared, i.e., by specific or class name, or § 501.100 to exempt an ingredient(s) from the requirements for label declaration.

[41 FR 38619, Sept. 10, 1976, as amended at 42 FR 15675, Mar. 22, 1977]
§ 582.5304 Ferric pyrophosphate. ( a ) *Product.* Ferric pyrophosphate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
DISTRICT COURT OF APPEAL OF THE STATE OF FLORIDA

FOURTH DISTRICT

FREDERICK FOSTER,

Appellant,

v.

STATE OF FLORIDA,

Appellee.

No. 4D17-2871

[December 7, 2017]

Appeal of order denying rule 3.800 motion from the Circuit Court for 

the Fifteenth Judicial Circuit, Palm Beach County; John S. Kastrenakes, 

Judge; L.T. Case Nos. 50 2002 CF 005030 and 50 2002 CF 000197.

Frederick Foster, Okaloosa, pro se.

No appearance required for appellee.

PER CURIAM.

Affirmed.

GROSS, TAYLOR and MAY, JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
United States Court of Appeals 

For the First Circuit 

No. 15–2192 

UNITED STATES OF AMERICA, 

Appellee, 

v. 

KING BELIN, 

Defendant, Appellant. 

ERRATA SHEET 

 The opinion of this Court issued on August 22, 2017, is 

amended as follows: 

 On page 19, line 17, the word "forego" is replaced with 

"forgo."
§ 524.1001 Fluralaner and moxidectin. ( a ) *Specifications.* Each milliliter of solution contains 280 milligram (mg) fluralaner and 14 mg moxidectin. Each individually packaged tube contains either 112.5 mg fluralaner and 5.6 mg moxidectin; 250 mg fluralaner and 12.5 mg moxidectin; or 500 mg fluralaner and 25 mg moxidectin.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer topically as a single dose every 2 months to provide a minimum dose of 18.2 mg/lb (40 mg/kg) fluralaner and 0.9 mg/lb (2 mg/kg) moxidectin.
( 2 ) *Indications for use.* For the prevention of heartworm disease caused by *Dirofilaria immitis* and for the treatment of infections with intestinal roundworm (*Toxocara cati,* fourth-stage larvae, immature adults, and adults) and hookworm (*Ancylostoma tubaeforme,* fourth-stage larvae, immature adults, and adults); kills adult fleas and is indicated for the treatment and prevention of flea infestations (*Ctenocephalides felis*) and the treatment and control of tick infestations (*Ixodes scapularis* (black-legged tick), *Dermacentor variabilis* (American dog tick), and *Haemaphysalis longicornis* (Asian longhorned tick)) for 2 months in cats and kittens 6 months of age and older and weighing 2.6 lb or greater.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[85 FR 18120, Apr. 1, 2020, as amended at 87 FR 58963, Sept. 29, 2022; 88 FR 14901, Mar. 10, 2023]
§ 601.7 Procedure for hearings. ( a ) A notice of opportunity for hearing, notice of appearance and request for hearing, and grant or denial of hearing for a biological drug pursuant to this part, for which the exemption from the Federal Food, Drug, and Cosmetic Act in § 310.4 of this chapter has been revoked, shall be subject to the provisions of § 314.200 of this chapter except to the extent that the notice of opportunity for hearing on the matter issued pursuant to § 12.21(b) of this chapter specifically provides otherwise.
( b ) Hearings pursuant to §§ 601.4 through 601.6 shall be governed by part 12 of this chapter.
( c ) When a license has been suspended pursuant to § 601.6 and a hearing request has been granted, the hearing shall proceed on an expedited basis.
[42 FR 4718, Jan. 25, 1977, as amended at 42 FR 15676, Mar. 22, 1977; 42 FR 19143, Apr. 12, 1977]
§ 556.495 Oxfendazole. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of oxfendazole is 7 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerance for fenbendazole (marker residue) is: ( 1 ) *Cattle.* Liver (target tissue): 0.8 ppm.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See §§ 520.1629 and 520.1630 of this chapter.
_______________________________________ __ Michigan Supreme Court 

# Order

Lansing, Michigan

October 4, 2006 Clifford W. Taylor, Chief Justice

129043 Michael F. Cavanagh
Elizabeth A. Weaver Marilyn Kelly Maura D. Corrigan JOHN POWELL, Plaintiff-Appellee, Robert P. Young, Jr. Stephen J. Markman,
Justices

v SC: 129043 COA: 261541 Court of Claims: 04-000077-MD DEPARTMENT OF TRANSPORTATION, Defendant-Appellant.

________________ _______________ __________/

On order of the Court, the application for leave to appeal the June 16, 2005 judgment of the Court of Appeals is consid ered and, pursuant to MCR 7.302(G)(1), in lieu of granting leave to appeal, we REVERS E the judgment of the Court of Appeals and
we REMAND this case to th e Court of Claims for entr y of an order granting the defendant’s motion for summary disposition. The plain tiff’s claim is barred by governmental immunity. The highway exce ption to governmental immunity does not apply because the shoulder of a highway is not part of the “imp roved portion of the highway designed for vehicular travel” fo r purposes of the highway exception to governmental immunity, MCL 691.1402(1), and is not “designed for vehicular travel.” Grimes v Dep’t of Transportation , 475 Mich 72, 73 (2006).

C AVANAGH , J., would deny leave to appeal.

s0927 I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

October 4, 2006

Clerk
EXHIBIT 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and accompanies the Quarterly Report on Form 10-Q (the “Form 10-Q”) for the quarter ended June 30, 2008 of Crimson Exploration Inc. (the “Issuer”).  The undersigned hereby certifies that the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Issuer. 

 

| Date:

  | August 12, 2008

                |   |
|---------------|---------------------------------------|--------|
|          | /s/ Allan D. Keel                     |   |
| Name:         | Allan D. Keel                         |   |
| Title:        | President and Chief Executive Officer |   |
|          |                                  |   |
|          |                                  |   |

 

A signed original of this written statement required by Section 906 has been provided to the Issuer and will be furnished to the Securities and Exchange Commission, or its staff, upon request.
§ 1306.03 Persons entitled to issue prescriptions. ( a ) A prescription for a controlled substance may be issued only by an individual practitioner who is: ( 1 ) Authorized to prescribe controlled substances by the jurisdiction in which he is licensed to practice his profession and
( 2 ) Either registered or exempted from registration pursuant to §§ 1301.22(c) and 1301.23 of this chapter.
( b ) A prescription issued by an individual practitioner may be communicated to a pharmacist by an employee or agent of the individual practitioner.
[36 FR 7799, Apr. 24, 1971, as amended at 36 FR 18732, Sept. 21, 1971. Redesignated at 38 FR 26609, Sept. 24, 1973, as amended at 62 FR 13966, Mar. 24, 1997]
**Exhibit 10.3**

 

**Crimson Exploration Inc.**

 

Crimson Long-Term Incentive Plan

 

*Eligibility*.

All employees are eligible to participate in the Crimson Long-Term Incentive Plan (the “*LTIP*”).  To be eligible, employees must be employed by Crimson Exploration Inc. (the “*Company*”) or one of its wholly owned subsidiaries at the time the final LTIP awards are paid.

 

*Plan Details*.

 

The LTIP bonus awards will be paid half in the form of restricted common stock and half in the form of stock options (the “*Stock Awards*”).  The Stock Awards will vest 25% per year, over the first through fourth anniversaries from the date of grant, at which time 100% of all Stock Awards will be vested.  The number of shares of restricted common stock and the number of shares underlying the stock options to be granted as Stock Awards will be determined based upon the fair market value of the common stock on the date of the grants in the first quarter of the following year.

 

Under the LTIP, each employee may receive a bonus award equal to a percentage of such employee’s base salary, with such percentage being determined by the Company’s performance relative to specific targeted performance measures.

 

The targeted performance measures under the LTIP are based on the following five categories:

 

|   | **•** | the amount of annual production |
|--------|------------|---------------------------------|

|   | **•** | the amount of “EBITDAX”1 |
|--------|------------|------------------------------------|

|   | **•** | the percentage of reserve replacement |
|--------|------------|---------------------------------------|

|   | **•** | the amount of total F&D2 cost; and |
|--------|------------|----------------------------------------|

|   | **•** | the percentage of ROIC3 |
|--------|------------|-------------------------|

 

The Compensation Committee sets the minimum, target and maximum levels for each of these categories for each fiscal year.

 

Under the LTIP, for all employees, each category comprises 20% of the bonus award.  When the Company’s performance with regards to a category falls between the minimum and the target amounts or between the target and maximum amounts, the bonus award will be a prorated accordingly.

 

The fair value of the stock options to be awarded as part of the LTIP will be determined through use of the Black-Scholes valuation model.  The Stock Awards granted pursuant to the LTIP will be granted under the existing amended and restated 2005 Stock Option Plan.

 

_________________________

1 Earnings Before Interest, Tax, Depreciation, Depletion, Amortization and Exploration Expenses

2 Finding & Development Costs

3 Return on Invested Capital
[Federal Register Volume 75, Number 8 (Wednesday, January 13, 2010)]
[Notices]
[Page 1796]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-424]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Complementary and Alternative Medicine; 
Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Complementary and 
Alternative Medicine Special Emphasis Panel, Clinical Science--
Review of NCCAM Clinical R21 and K Applications.
    Date: February 25-26, 2010.
    Time: 9 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military 
Road, NW., Washington, DC 20015.
    Contact Person: Laurie Friedman Donze, PhD, Scientific Review 
Officer, Office of Scientific Review, National Center for 
Complementary, and Alternative Medicine, NIH, 6707 Democracy Blvd., 
Suite 401, Bethesda, MD 20892, 301-402-1030, <a href="/cdn-cgi/l/email-protection#20444f4e5a454c604d41494c0e4e49480e474f56"><span class="__cf_email__" data-cfemail="0e6a6160746b624e636f67622060676620696178">[email protected]</span></a>.

    Name of Committee: National Center for Complementary and 
Alternative Medicine Special Emphasis Panel, P50 Botanical Centers.
    Date: March 3-5, 2010.
    Time: 5 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Courtyard Marriott Washingtonian Center, 204 Boardwalk 
Place, Gaithersburg, MD 20814.
    Contact Person: Martina Schmidt, PhD, Scientific Review Officer, 
Office of Scientific Review, National Center for Complementary, and 
Alternative Medicine, NIH, 6707 Democracy Blvd., Suite 401, 
Bethesda, MD 20892, 301-594-3456, <a href="/cdn-cgi/l/email-protection#3546565d585c5158547558545c591b5b5c5d1b525a43"><span class="__cf_email__" data-cfemail="0f7c6c6762666b626e4f626e66632161666721686079">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.213, 
Research and Training in Complementary and Alternative Medicine, 
National Institutes of Health, HHS)

    Dated: January 7, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-424 Filed 1-12-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>